What is Torigen Pharmaceuticals?
Torigen Pharmaceuticals Inc. operates at the intersection of biotechnology and veterinary care, specializing in the development of immuno-oncology products for companion animals. The company's core innovation involves a patented process that utilizes a portion of a pet's own tumor to synthesize a personalized cancer vaccine. This approach is designed to stimulate the animal's immune system to recognize and combat tumor-associated antigens, effectively reversing immune senescence. With over a decade of pre-clinical research supporting its methodology, Torigen is positioned as a leader in veterinary biologics, addressing a significant unmet need in the pet healthcare market for affordable and effective oncology solutions.
How much funding has Torigen Pharmaceuticals raised?
Torigen Pharmaceuticals has raised a total of $16.1M across 2 funding rounds:
Series A
$3.1M
Series A
$13M
Series A (2019): $3.1M with participation from Connecticut Innovations
Series A (2022): $13M led by Connecticut Innovations, Gaingels, and Emerald Development Managers
Key Investors in Torigen Pharmaceuticals
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
Gaingels
Gaingels is a leading investment syndicate representing the LGBTQ community and allies, deploying capital into high-growth companies while advocating for inclusive leadership and diverse board representation across various sectors.
Emerald Development Managers
Emerald Development Managers is a venture capital firm that invests in exceptional scientific and engineering teams focused on solving real-world problems, specializing in sectors such as life sciences, enterprise software, and sustainability.
What's next for Torigen Pharmaceuticals?
With the recent infusion of capital, Torigen Pharmaceuticals is well-positioned to accelerate its clinical development programs and expand its commercial footprint. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet the growing demand for personalized veterinary biologics and deepening its research into broader immuno-oncology applications. As the firm transitions from early-stage development to a more mature enterprise-level operation, the focus will remain on validating its therapeutic efficacy through rigorous clinical trials and establishing a robust distribution network. This financial backing provides the necessary runway to solidify its market leadership and potentially disrupt traditional veterinary oncology standards.
See full Torigen Pharmaceuticals company page
